Sanofi Consumer Healthcare India Reports Q3'26 Financial Results
Sanofi Consumer Healthcare India Ltd · Outcome · 29 Oct 2026, 12:16 am
Sanofi Consumer Healthcare India Reports Q3'26 Financial Results Sanofi Consumer Healthcare India reported a 12.48% YoY increase in revenue from operations to ₹2,631 million for the quarter ended 30th Sep'26, compared to ₹2,339 million in the previous year quarter. Net profit rose 21.78% YoY to ₹766 million from ₹629 million, with Profit Before Tax expanding 22.12% YoY to ₹1,027 million. Basic and diluted EPS improved to ₹33.26 from ₹27.31 YoY. For 9M'26, revenue stood at ₹7,280 million, up 16.03% YoY, while net profit grew 22.81% YoY to ₹2,132 million.
Original exchange filing (PDF)
More announcements from Sanofi Consumer Healthcare India Ltd
- Sanofi Consumer Healthcare India Limited has informed the Exchange regarding a press release dated October 28, 2026. · 29 Oct 2026
- The Board of Directors at its meeting held on Wednesday, 28th October 2026, considered and approved the Unaudited Financial Results for the quarter and nine months ended 30th September .... · 29 Oct 2026
- Unaudited Financial Results for the quarter and nine months ended September 30, 2026 is enclosed. · 29 Oct 2026
- We wish to inform you that the Board of Directors at its meeting held today, i.e. Wednesday, 28th October 2026, inter alia considered and approved the Unaudited Financial Results for the .... · 28 Oct 2026
- Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 28 Oct 2026
- Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve the Unaudited .... · 28 Oct 2026
- Sanofi Consumer Healthcare India Limited has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 . · 28 Oct 2026
- To consider and approve the Unaudited Financial Results for the quarter and nine months ended September 30, 2026 · 28 Oct 2026
